Theravance Biopharma Inc (F:0TB) — Market Cap & Net Worth
Market Cap & Net Worth: Theravance Biopharma Inc (0TB)
Theravance Biopharma Inc (F:0TB) has a market capitalization of $828.57 Million (€708.72 Million) as of August 15, 2026. Listed on the F stock exchange, this Germany-based company holds position #9776 globally and #1197 in its home market, demonstrating a 0.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theravance Biopharma Inc's stock price €14.50 by its total outstanding shares 50672431 (50.67 Million). See debt-free asset ratio of Theravance Biopharma Inc to understand what proportion of total assets are financed by equity.
Theravance Biopharma Inc Market Cap History: 2015 to 2026
Theravance Biopharma Inc's market capitalization history from 2015 to 2026. Data shows growth from $896.62 Million to $859.00 Million (1.69% CAGR). Also see 0TB total asset value for a full breakdown of the balance sheet.
Theravance Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theravance Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Theravance Biopharma Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.37x
Theravance Biopharma Inc's market cap is 8.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $896.62 Million | $42.13 Million | -$182.22 Million | 21.28x | N/A |
| 2016 | $1.78 Billion | $48.65 Million | -$190.67 Million | 36.51x | N/A |
| 2017 | $1.40 Billion | $15.39 Million | -$285.40 Million | 91.07x | N/A |
| 2018 | $1.19 Billion | $60.37 Million | -$215.52 Million | 19.75x | N/A |
| 2019 | $1.36 Billion | $73.41 Million | -$236.46 Million | 18.56x | N/A |
| 2020 | $853.08 Million | $71.86 Million | -$278.02 Million | 11.87x | N/A |
| 2021 | $550.94 Million | $55.31 Million | -$199.43 Million | 9.96x | N/A |
| 2022 | $616.11 Million | $51.35 Million | $872.13 Million | 12.00x | 0.71x |
| 2023 | $604.26 Million | $57.42 Million | -$55.19 Million | 10.52x | N/A |
| 2024 | $539.10 Million | $64.38 Million | -$56.42 Million | 8.37x | N/A |
Competitor Companies of 0TB by Market Capitalization
Companies near Theravance Biopharma Inc in the global market cap rankings as of August 15, 2026. Also see Theravance Biopharma Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Key companies related to Theravance Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #224 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #429 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #553 globally with a market cap of $49.06 Billion USD ( ₩72.40 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #224 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $516.44 |
| #429 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $805.97 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €754.40 |
| #553 | Samsung Biologics Co Ltd | KO:207940 | $49.06 Billion | ₩1564000.00 |
Theravance Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Theravance Biopharma Inc's market cap moved from $896.62 Million to $ 859.00 Million, with a yearly change of 1.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €859.00 Million | -7.64% |
| 2025 | €930.09 Million | +72.53% |
| 2024 | €539.10 Million | -10.78% |
| 2023 | €604.26 Million | -1.92% |
| 2022 | €616.11 Million | +11.83% |
| 2021 | €550.94 Million | -35.42% |
| 2020 | €853.08 Million | -37.39% |
| 2019 | €1.36 Billion | +14.26% |
| 2018 | €1.19 Billion | -14.89% |
| 2017 | €1.40 Billion | -21.10% |
| 2016 | €1.78 Billion | +98.07% |
| 2015 | €896.62 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 14th, 2026 the market cap of Theravance Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $828.57 Million USD |
| MoneyControl | $828.57 Million USD |
| MarketWatch | $828.57 Million USD |
| marketcap.company | $828.57 Million USD |
| Reuters | $828.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more